MedTrace Logo

SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy

NCT05044754 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-09-16

No results posted yet for this study

Summary

The evidence base relating to the use of SCAP and HIFU is poor, with significant uncertainties relating to long-term oncological outcomes. One of the main limitations when the few studies reported are analyzed is the lack of information about the histopathology both before starting treatment and at the time of recurrence after cryotherapy. The vast majority of studies refer only to BCR-free survival as end point, thus limiting interpretation of real oncological performance of this technique. Furthermore, side effects vary widely from study to study and there are uncertainties about the real morbidity associated to cryotherapy in the salvage setting.

Another important hot issue in this scenario is the potential benefit that new imaging and diagnosis techniques (MRI, targeted biopsy, PSMA) may add for a more accurate indication. This could provide the possibility of better results for SCAP. The clinical value of this new diagnostic tools is unknown in this scenario and needs to be explored.

Conditions

  • Cryotherapy
  • High Intensity Focused Ultrasounds
  • Recurrent Prostate Cancer

Interventions

PROCEDURE

Local treatment of the prostate (SCAP or HIFU)

Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)

Sponsors & Collaborators

  • Hospital Universitario Reina Sofia de Cordoba

    collaborator OTHER_GOV

  • Hospitales Universitarios Virgen del Rocío

    collaborator OTHER

  • Institut Universitaire du Cancer de Toulouse

    collaborator OTHER

  • University Hospital Virgen de las Nieves

    lead OTHER

Principal Investigators

  • Ignacio Puche-Sanz, MD, PhD · University Hospital Virgen de las Nieves

  • Enrique Gomez-Gomez, MD · Hospital Universitario Reina Sofia de Cordoba

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-10-01
Completion
2024-10-01

Countries

  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05044754 on ClinicalTrials.gov